Skip to main content may receive compensation from affiliate partners for some links on the site. Read our full Disclosure here.

U.S. Federal Government Attempts to Ban Nasal Spray That Company Claims Is Scientifically Proven to Be Effective Against COVID-19


What if I told you a simple nasal spray showed positive results treating and preventing COVID-19?

The nasal spray contained only a handful of ingredients and presented no risk factors?

And the nasal spray is commercially available at an affordable cost without the need for a prescription.

If that sounds believable, you won’t be surprised to learn the U.S. federal government wants to ban that nasal spray.

That’s the situation we find ourselves in with a nasal spray called Xlear.

What is Xlear?

Xlear is a natural saline spray that helps relieve congestion.

The spray cleanses to prevent bacteria and other pollutants from sticking to nasal tissues.

The formula adds xylitol to cleanse and moisturize the inside of the nose and nasal passages to prevent dryness.

Xlear’s primary ingredients are saline, grapefruit seed extract, and xylitol, a plant-derived sweetener commonly used in oral care products.

And the Utah-based company states its nasal spray is an effective treatment and preventative of COVID-19.

Xlear has multiple studies to back up their claims and the federal government has filed a lawsuit to ban the company from promoting the nasal spray as such.

From The Epoch Times via Zero Hedge:

The U.S. Department of Justice filed a lawsuit in federal court against Utah-based company Xlear on Oct. 28, saying it has deceptively advertised its nasal spray as a treatment and preventative of COVID-19.

The lawsuit asks a federal court to permanently ban the company from promoting the nasal spray as a treatment for COVID-19 and also asks that monetary penalties be levied against it.

COVID-19 is the disease caused by SARS-CoV-2, commonly known as the novel coronavirus.

The DOJ filed the complaint on behalf of the Federal Trade Commission, which alleges the company has violated the Federal Trade Commission Act and the Consumer Protection Act by making false claims about the benefits.


“Companies can’t make unsupported health claims, no matter what form a product takes, or what it supposedly prevents or treats,” said Samuel Levine, director of the trade commission’s Bureau of Consumer Protection, said in a press release on the lawsuit.

“That’s the lesson of this case and many others like it, and it’s why people should continue to rely on medical professionals over ads.”

Xlear’s attorney Robert Housman stated the commission is lying about the company’s claim not being supported.

cont. from The Epoch Times via Zero Hedge:

Housman pointed out that the National Institute of Allergy and Infectious Diseases (NIAID)—along with the National Institutes of Health (NIH), an arm of the Department of Health and Human Services—funded clinical studies of the use of nasal sprays like Xlear’s and published findings last year that found they were an effective treatment and method of prevention for COVID-19.

“When Xlear tells people about scientific studies, even ones republished by the NIH, we are somehow misleading people and making false claims. It’s nonsensical,” Housman told The Epoch Times.

Rather than embrace nasal interventions, the government is trying to eliminate their use because they don’t fit the government’s highly flawed, vaccine-only agenda.

One scientific study that researched the nasal spray’s effectiveness against COVID-19 was supported by the NIH.

The random clinical trial took place at the Vanderbilt University Medical Center in Tennessee and investigated the use of nasal saline irrigations to treat COVID-19.

Read the findings from the September 2020 study:

Nasal saline irrigation is a commonly accepted and inexpensive therapy with proven efficacy as a treatment for viral upper respiratory infections and has been proposed as a potentially beneficial treatment for COVID-19.9 Here, we present initial findings from the first RCT evaluating nasal irrigations in non-hospitalized patients with COVID-19. The effect of nasal irrigation on symptom resolution was substantial, with nasal congestion and headache resolving a median of 7 to 9 days earlier in the intervention groups. Our analysis suggests that nasal irrigations may shorten symptom duration and may have potential as a widely available and inexpensive intervention to reduce disease burden among those affected. The additive effects of surfactant remain unclear, because the impact of HTS and HTSS on symptom resolution was fairly equivalent, and it has been reported that surfactant nasal irrigations are associated with some tolerability issues in a subset of patients.10 However, the addition of surfactant may have beneficial effects on viral shedding and/or maturation given their reported ability to rapidly induce membrane dissolution and lysis of many viruses and other microorganisms.

After the positive results from the September 2020 clinical trial, an additional study conducted in November 2020 showed promising figures.

Held at Larkin Community Hospital in Florida, the nasal spray eased COVID-19 symptoms in half the time.

An ongoing trial in Augusta, Georgia has thus far shown remarkable results in patients who receive daily nasal irrigation.

Conclusion SARS-CoV-2+ participants initiating nasal irrigation were over 8 times less likely to be hospitalized than the national rate.

Despite multiple trials that show positive results, the U.S. Department of Justice ignored the findings in their lawsuit.

From Collective Spark:

The Justice Department didn’t specifically cite the Larkin, Vanderbilt, or Augusta trials in its lawsuit.

It instead cited the results of lab studies conducted earlier at the University of North Carolina–Chapel Hill and the University of Tennessee involving in vitro and animal testing, neither of which the DOJ and FTC argue is a viable way to test nasal spray for live, human COVID-19 patients.

The lawsuit additionally pointed out that the University of Tennessee study is based on a nasal spray containing iota-carrageenan, which the Xlear spray does not contain and, therefore, cannot be used as scientific evidence to support Xlear’s claims.

The lawsuit also stated that researchers at Chapel Hill admitted that without further research it couldn’t conclusively determine that “administering treatment through the nose is the best way to treat COVID-19.”

Housman said the trade commission cherry-picked findings within the lab studies to make them fit its agenda.

The federal government has warned companies against promoting nasal sprays for the treatment and prevention of COVID-19.

BlueWillow Biologics, a Michigan biopharmaceutical company that manufactures a nasal antiseptic, and the Miami-based company Halodine, which created a proprietary iodine-based nasal antiseptic swab, both received warning letters earlier this year from the FDA to discontinue their promotion of their nasal products as a safe and effective treatment for COVID-19.

The U.S. federal government is determined to destroy Xlear and cease promoting the nasal spray’s benefits against COVID-19.

That’s because it would undermine the government’s vaccination agenda.

*A Special Disclaimer*

Before you seek Xlear nasal spray or any other treatment, consult your physician to determine what’s right for you.

I’m not a doctor and DO NOT recommend anything without prior physician consultation.

I am simply reporting on these developments.


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

We Love Trump
Thanks for sharing!